In short
Elezanumab, also known as ABT-555, is an investigational drug being studied in clinical trials for various neurological conditions. These trials aim to assess the safety and efficacy of Elezanumab in treating acute spinal cord injury, acute ischemic stroke, and multiple sclerosis. The drug is administered through intravenous infusion and is being evaluated for its potential to improve neurological function and promote neuroregeneration in patients with these challenging conditions.
At a glance
- Drug Name
- Elezanumab (ABT-555)
- Administration Method
- Intravenous (IV) infusion
- Conditions Studied
- Acute Spinal Cord Injury (SCI), Acute Ischemic Stroke, Multiple Sclerosis (MS) - Progressive and Relapsing forms
- Trial Design
- Randomized, Double-Blind, Placebo-Controlled
- Primary Outcomes
- Changes in neurological function, disability improvement, overall response scores
- Assessment Tools
- NIHSS, mRS, EDSS, UEMS, ORS, SCIM III
- Treatment Duration
- Typically 48-52 weeks, with doses every 4 weeks
- Mechanism of Action
- Binds to an inhibitor of neuronal regeneration, potentially promoting neuroregeneration
What is Elezanumab?
Elezanumab, also known as ABT-555, is an investigational drug currently being studied for its potential to treat various neurological conditions. As an investigational drug, it has not yet been approved by regulatory agencies for widespread use, but is undergoing clinical trials to assess its safety and effectiveness.
What Conditions Does Elezanumab Treat?
Elezanumab is being investigated for several neurological conditions, including:
- Acute Spinal Cord Injury (SCI): A sudden injury to the spinal cord that can lead to permanent neuromotor impairment and disability.
- Acute Ischemic Stroke: A type of stroke caused by a blockage in blood flow to the brain, which can result in neurological deficits.
- Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, including both progressive and relapsing forms.
How Does Elezanumab Work?
Elezanumab is a monoclonal antibody, which is a type of protein designed to target specific molecules in the body. In the case of Elezanumab, it binds to and neutralizes an inhibitor of neuronal regeneration. By doing so, it may potentially promote neuroregeneration, which is the regrowth or repair of nervous system tissues. This mechanism of action makes it a promising candidate for conditions involving damage to the nervous system.
How is Elezanumab Administered?
Elezanumab is administered as an intravenous (IV) infusion. This means it is given directly into the bloodstream through a vein. The frequency and duration of treatment can vary depending on the condition being treated and the specific clinical trial protocol.
Current Clinical Trials
Several clinical trials are currently underway to evaluate Elezanumab:
- A study for acute ischemic stroke, where participants receive the drug within 24 hours of stroke onset and then every 4 weeks for 48 weeks.
- Trials for both progressive and relapsing forms of Multiple Sclerosis, testing different doses of Elezanumab against a placebo.
- A study for acute traumatic cervical spinal cord injury, administering the drug within 24 hours of injury and every 4 weeks thereafter for 48 weeks.
How is Elezanumab's Effectiveness Measured?
Researchers use various scales and measures to assess the effectiveness of Elezanumab, including:
- National Institutes of Health Stroke Scale (NIHSS): Used in stroke studies to measure the severity of stroke symptoms.
- Overall Response Score (ORS): A composite score used in Multiple Sclerosis trials, derived from several functional assessments.
- Upper Extremity Motor Score (UEMS): Used in spinal cord injury studies to assess function in the upper limbs.
- Spinal Cord Independence Measures (SCIM III): Evaluates self-care abilities in spinal cord injury patients.
Potential Benefits of Elezanumab
While the full benefits of Elezanumab are still being investigated, the drug shows promise in several areas:
- Potential to improve neurological function in stroke patients.
- Possible reduction in disability progression in Multiple Sclerosis.
- Potential to enhance upper limb function in spinal cord injury patients.
It's important to note that as an investigational drug, the full safety profile and efficacy of Elezanumab are still being determined through ongoing clinical trials. Patients interested in this treatment should consult with their healthcare providers about the possibility of participating in clinical trials or accessing the drug through expanded access programs where available.